On December 4, 2025, Denali Therapeutics Inc. shared key updates on their development pipeline during the 2025 Investor Day, including timelines for drug approvals, with a target action date for their drug tividenofusp alfa set for April 5, 2026. This filing highlights ongoing clinical studies and important regulatory engagement, crucial for investors to monitor.